人を対象とした研究倫理室

Keyphrases

1. Esophageal Squamous Cell Carcinoma 100%
2. Tumor 44%
3. P75 Neurotrophin Receptor (p75NTR) 42%
4. Circulating Tumor Cells 37%
5. Esophageal Cancer 26%
6. Prognostic Significance 26%
7. Cluster of Differentiation 44 (CD44) 25%
8. Gastric Cancer 25%
9. MicroRNA 22%
10. Epithelial Cell Adhesion Molecule (EpCAM) 20%
11. Nanog 20%
12. Esophagectomy 19%
13. Carcinoma Cell Lines 17%
14. Human Esophageal Squamous Cell Carcinoma 17%
15. Gallbladder Cancer 16%
16. Receptor Expression 16%
17. Gastric Cancer Patients 15%
18. GLUT3 15%
19. Bone Marrow Cells 15%
20. Cancer Stem Cells 15%
21. Subtotal Esophagectomy 14%
22. Cancer Cells 13%
23. Glucose Transporter 1 (GLUT1) 13%
24. Indocyanine Green Fluorescence 13%
25. Jejunum 13%
26. Clinical Significance 12%
27. Cancer Stem Cell Markers 12%
28. Stomach 12%
29. Overexpression 12%
30. Expression Analysis 11%
31. Breast Cancer Patients 11%
32. Resection 11%
33. Stem Cell Markers 11%
34. KLF4 11%
35. After Surgery 11%
36. Blood Supply 10%
37. Expression Level 10%
38. Gastric Cancer Stem Cells 10%
39. Anastomosis 10%
40. General Surgery 10%
41. 18F-fluorodeoxyglucose (18F-FDG) 10%
42. Pancreaticoduodenectomy 10%
43. Gastrointestinal Stromal Tumor 10%
44. Desmoid Tumor 10%
45. Abdominal Wall 10%
46. Digestive Surgery 10%
47. Aquaporin 5 (AQP5) 10%
48. Esophageal Leiomyoma 10%
49. Single-center Study 10%
50. Gastric Tube 10%
51. Fibroblast Growth Factor Receptor 1 (FGFR1) 10%
52. Carbon Ion Radiotherapy 10%
53. Tissue Microarray 10%
54. Peripheral Blood 10%
55. Postoperative Outcomes 10%
56. Cell Subsets 10%
57. Pancreatic Cancer 10%
58. Quantitative PCR 9%
59. Lymph Node Metastasis 9%
60. Esophageal Squamous Carcinoma Cell 9%
61. Gemcitabine 9%
62. Postoperative Day 9%
63. Total Gastrectomy 9%
64. Multidisciplinary Treatment 8%
65. KRAS mutation 8%
66. Curative Surgery 8%
67. Radical Esophagectomy 8%
68. CD90 7%
69. Conservative Treatment 7%
70. Mesenchymal Stem Cells 7%
71. Helicobacter 7%
72. Colony Formation 7%
73. Metastatic Potential 7%
74. Multivariate Analysis 7%
75. Green Fluorescent Protein 7%
76. Induced Pluripotent Stem Cells (iPSCs) 7%
77. Esophageal Cancer Cells 7%
78. Portal Vein 7%
79. Independent Prognostic Factor 7%
80. Formalin-fixed Paraffin-embedded Tissue 7%
81. Older Women 6%
82. Anastomotic Leakage 6%
83. C-kit 6%
84. Older Men 6%
85. Gastric Tissue 6%
86. Cell Surface Markers 6%
87. Fluorine-18-fluorodeoxyglucose Positron Emission Tomography 6%
88. Thoracoscopic Esophagectomy 6%
89. Anticancer Drugs 6%
90. Overall Survival 6%
91. Poor Prognosis 6%
92. Enucleation 6%
93. Biological Role 6%
94. Preoperative Chemotherapy 6%
95. Pathological Diagnosis 6%
96. Barrett's Adenocarcinoma 6%
97. Stem Cell Population 5%
98. Newly Established 5%
99. Perforation 5%
100. Postoperative Prognosis 5%

Medicine and Dentistry

1. Esophageal Squamous Cell Carcinoma 93%
2. Neoplasm 57%
3. Esophagectomy 55%
4. Neurotrophin Receptor P75 37%
5. Esophageal Cancer 29%
6. Abdominal Cancer 29%
7. Cancer Stem Cell 28%
8. Circulating Tumor Cell 26%
9. microRNA 25%
10. Cell Marker 24%
11. Esophagus 22%
12. In Vitro 20%
13. Epithelial Cell Adhesion Molecule 19%
14. Stem Cell 18%
15. Surgery 17%
16. Metastatic Carcinoma 16%
17. Receptor Expression 16%
18. Glucose Transporter 3 15%
19. Pancreas Cancer 14%
20. Jejunum 13%
21. Glucose Transporter 1 13%
22. Indocyanine Green 13%
23. Surgical Anastomosis 13%
24. Messenger RNA 12%
25. Cancer Cell 12%
26. Gemcitabine 12%
27. Carcinogenesis 11%
28. Cell Line 11%
29. Vascularity 11%
30. Malignant Neoplasm 11%
31. Lymph Node Metastasis 11%
32. Fluorine-18 11%
33. Fluorodeoxyglucose 11%
34. Prognostic Factor 10%
35. Fluorodeoxyglucose F 18 10%
36. Gastrointestinal Stromal Tumor 10%
37. Abdominal Wall 10%
38. Desmoid Tumor 10%
39. Pancreaticoduodenectomy 10%
40. Angioleiomyoma 10%
41. Ion Therapy 10%
42. Aquaporin 5 10%
43. Mesenchymal Stem Cell 10%
44. Fibroblast Growth Factor Receptor 10%
45. Gallbladder Carcinoma 10%
46. Xenograft 9%
47. Adenocarcinoma 9%
48. Total Stomach Resection 9%
49. Dysplasia 8%
50. Conservative Treatment 8%
51. Hepatic Portal Vein 8%
52. Anastomosis Leakage 8%
53. Chemotherapy 7%
54. Intraepithelial Neoplasia 7%
55. Adjuvant Chemotherapy 7%
56. Clinical Significance 7%
57. Diagnosis 7%
58. Upregulation 7%
59. Tumor Progression 7%
60. Esophageal Squamous Cell Carcinoma Cell Line 7%
61. Multivariate Analysis 7%
62. Green Fluorescent Protein 6%
63. Epithelial Cell 6%
64. Reverse Transcription Polymerase Chain Reaction 6%
65. Cell Count 6%
66. Cell Proliferation 6%
67. Cell Surface Marker 6%
68. Expression Analysis 6%
69. Progenitor Cell 6%
70. Flow Cytometry 6%
71. Biological Marker 6%
72. Chemoradiotherapy 6%
73. Small Interfering RNA 6%
74. Enucleation 6%
75. Sigmoid 6%
76. Oncology 6%
77. Positron Emission Tomography 5%
78. Cell Population 5%
79. Short Hairpin RNA 5%
80. Serositis 5%
81. Overall Survival 5%
82. Keratin 19 5%
83. Helicobacter 5%
84. Metastasis Potential 5%
85. Lymphoma 5%
86. Aquaporin 5%
87. Gallbladder Carcinoma Cell Line 5%
88. Prone Position 5%
89. Colon 5%
90. Colony Formation 5%
91. Rivaroxaban 5%
92. Venous Stasis 5%
93. Outcome Assessment 5%
94. Neurinoma 5%
95. Splenomegaly 5%
96. Hairy Cell Leukemia 5%
97. RNA Vector 5%
98. Autoimmune Pancreatitis 5%
99. Mobilization 5%
100. Bronchogenic Cyst 5%